Erschienen in:
22.08.2023 | Adis Drug Q&A
Linzagolix in moderate to severe symptoms of uterine fibroids: a profile of its use
verfasst von:
Simon Fung, Hannah A. Blair
Erschienen in:
Drugs & Therapy Perspectives
|
Ausgabe 9/2023
Einloggen, um Zugang zu erhalten
Abstract
Linzagolix (Yselty®) is an orally administered gonadotropin-releasing hormone receptor antagonist approved in the EU for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age and extends the treatment options in this indication. Linzagolix is available as different treatment regimens: for short-term use to reduce uterine and fibroid volumes; and for longer-term use to manage fibroid-associated symptoms. In two placebo-controlled phase 3 trials, linzagolix as a single agent or in combination with hormonal add-back therapy significantly reduced the proportion of patients with heavy menstrual bleeding, improved other symptoms associated with uterine fibroids (including anaemia and pain) and improved patient quality of life. Linzagolix was generally well tolerated, with hot flushes and headaches being the most common adverse events.